VRDN
ViridianยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
VRDN Profile
Viridian Therapeutics, Inc.
A clinical-stage biopharmaceutical company that developing drugs for autoimmune disease and thyroid eye disease
Pharmaceutical
06/17/2014
06/18/2014
NASDAQ Stock Exchange
143
12-31
Common stock
221 Crescent Street, Suite 401, Waltham, MA 02453
--
Founded in Delaware on June 17, 2014, Viridian Therapeutics, Inc., is a biopharmaceutical company focused on the research and development of potentially optimal medicines for serious and rare diseases. The company is targeting less competitive disease areas where marketed therapies often leave room for improved efficacy, safety or ease of administration. The company believes that first-generation drugs rarely represent the best solution, especially in the field of rare diseases, and have the potential to develop differentiated, best-in-class drugs that improve patient outcomes, reduce side effects, improve quality of life, expand market access and enhance market competition. The company is developing three product candidates: VRDN-001, VRDN-002 and VRDN-003, which are under development for intravenous or subcutaneous injection to treat patients with thyroid eye disease (TED). The company's most advanced project, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R for the treatment of TED.
